Boc-Asp(OMe)-OH

Boc-Asp(OMe)-OH is a protected aspartic acid derivative featuring a Boc-protected alpha-amino group and a methyl ester on the side-chain carboxyl function. This functional group pattern makes it a practical building block for assembling aspartate-containing peptide segments while controlling side-chain reactivity during coupling and deprotection steps. In peptide and intermediate synthesis workflows, the esterified side chain helps maintain solubility and suppress unwanted side reactions until the desired stage of sequence construction.

1. Solid-Phase Peptide Synthesis

Boc-Asp(OMe)-OH is frequently used as a protected aspartate building block in peptide synthesis workflows where the side-chain carboxyl is intentionally masked as a methyl ester. Peptide synthesis groups incorporate this derivative to build peptide sequences containing Asp residues with reduced risk of side-chain participation during early coupling steps, supporting cleaner segment assembly and minimizing byproducts associated with carboxyl reactivity. Because the amino functionality is protected as Boc, it aligns with Boc-based synthetic strategies commonly used for generating aspartate-bearing peptides and peptide fragments for downstream purification and characterization.

2. Aspartate-Containing Segment Building

Boc-Asp(OMe)-OH serves as a targeted intermediate for preparing aspartate-rich peptide segments and defined oligopeptides in both research and custom manufacturing settings. Synthetic teams select the OMe side-chain ester form to improve handling during fragment condensation and to keep the Asp side chain in a controlled state while the peptide backbone is extended. This approach is particularly useful when the project requires a later, deliberate conversion of the side-chain carboxyl functionality to the desired form for final peptide properties, such as charge state control and compatibility with subsequent conjugation or derivatization steps.

3. Pharmaceutical Intermediate Development

Boc-Asp(OMe)-OH is also used in medicinal chemistry and process development contexts as a protected aspartate intermediate for constructing more complex molecules that incorporate an Asp-derived motif. Chemical development groups value the orthogonal protection pattern provided by the Boc amino group and the methyl ester side chain because it enables stepwise elaboration of functional groups without premature exposure of both carboxyl functionalities. This makes the compound a practical input for building blocks used in the synthesis of peptidomimetic scaffolds, protected amino-acid-derived fragments, and related specialty intermediates where controlled functional-group presentation is required for reliable downstream transformations.

4. Peptide Derivatization Precursors

Boc-Asp(OMe)-OH is commonly selected when the aspartate residue must be introduced into a protected peptide framework prior to later functionalization of the side-chain carboxyl group. Research groups use this derivative to prepare peptide intermediates that can be carried through purification and analytical verification before converting the Asp side chain to a reactive or differently protected carboxyl state for subsequent steps such as derivatization, linker installation, or compatibility with downstream conjugation chemistry. The methyl ester side-chain protection helps keep the peptide intermediate chemically defined during handling, supporting reproducible downstream processing in peptide-focused chemical biology workflows.

1. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma